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The search for crystalluria and morphologic analysis of urinary crystals is of interest in the
diagnostic evaluation and assessment of efﬁcacy of therapeutic strategies in stone formers.
In common calcium oxalate (CaOx) nephrolithiasis, identiﬁcation of the monohydrate or
dihydrate form of CaOx orients toward hyperoxaluria or hypercalciuria as the main
lithogenic mechanism, respectively. An unusual high abundance of crystals exclusively
made of CaOx monohydrate is highly suggestive of primary hyperoxaluria, the most severe
of all types of renal stone diseases. The identiﬁcation of crystal species such as struvite,
cystine, 2,8-dihydroxyadenine, which are not found in normal urine, is indicative of spe-
ciﬁc pathological conditions, namely, infection stones and hereditary diseases such as
cystinuria and dihydroxyadeninuria. Such diseases expose to progressive loss of renal
function unless they are prevented by speciﬁc therapeutic measures. The presence of
crystals made of drugs may entail the risk of kidney dysfunction because of crystallization
of the drug or its metabolites.
Serial determination of crystalluria, which reﬂects the activity of stone disease and its
response to therapeutic measures, is of major interest in the follow-up of patients suffering
from nephrolithiasis. It should be more largely used in clinical practice in most stone
formers, still more for the surveillance of patients affected by severe, hereditary renal
stone diseases such as primary hyperoxaluria, cystinuria, and dihydroxyadeninuria, where
determination of the global crystal volume allows assessing the efﬁcacy of therapeutic
measures and optimizing the medical management of the patients.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).vice des Explorations Fonctionnelles, 4, rue de la Chine, 75970 Paris cedex 20, France.
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L’etude de la cristallurie et de ses caracteristiques qualitatives et quantitatives est d'un
intere^t clinique majeur pour le diagnostic de la maladie lithiasique et l’evaluation de
l'efﬁcacite des mesures therapeutiques proposees aux patients. Dans la lithiase oxalo-
calcique commune, la forme cristalline, whewellite ou weddellite, oriente respectivement
vers une hyperoxalurie ou une hypercalciurie. Une quantite elevee de cristaux de whe-
wellite traduit une forte hyperoxalurie et doit faire rechercher une hyperoxalurie primaire.
L'identiﬁcation de cristaux particuliers tels que la struvite, la cystine, la dihydroxy-2,8-
adenine permet le diagnostic de pathologies speciﬁques qui exposent a une alteration
progressive de la fonction renale lorsqu'elles ne sont pas traitees precocement par des
mesures adaptees. La presence de cristaux medicamenteux peut expliquer l'origine d'une
insufﬁsance renale aigu€e developpee sous traitement.
Au cours du suivi des patients souffrant de lithiase, la determination de la cristallurie sur
des prelevements series est d'un grand intere^t pour la prevention du risque de recidive de
calculscar elle reﬂete l'activite de la maladie lithiasique et sa reponse aux mesures
dietetiques et therapeutiques. Elle peut donc beneﬁcier a la plupart des patients lithia-
siques. Elle se doit d’e^tre realisee chez tout patient souffrant d'une forme hereditaire
severe de lithiase telle que cystinurie, hyperoxalurie primaire ou dihydroxyadeninurie
pour en optimiser la prise en charge therapeutique, la determination du volume cristallin
global dans ces pathologies cristallines severes permettant d'adapter le traitement
medical, d’evaluer l'efﬁcacite des mesures therapeutiques proposees et de modiﬁer celles-
ci en fonction des resultats obtenus.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Formation of crystals in renal tubules is the obligatory
initial step in stone formation. However, crystalluria, that
is, the presence of crystals in urine, is a natural phenome-
non resulting from urine supersaturation and may only
reﬂect transiently low urine volume and/or high solute
output. Indeed, the presence of crystals made of common
constituents such as calcium oxalate (CaOx), calcium
phosphate (CaP), or uric acid (UA) may occur in nonlithiasic
subjects and is not a pathological ﬁnding per se, although
the occurrence of crystalluria was found to be signiﬁcantly
more frequent in stone formers than in healthy subjects
[1e3].
The search for crystalluria and analysis of the charac-
teristics of urinary crystals is of interest in the laboratory
evaluation of a stone former in several ways: (i) CaOx, CaP,
and UA present as different crystalline phases which reﬂect
different lithogenic risk factors; (ii) unusual morphology or
abundance of crystals made of common constituents may
orient toward peculiar etiologies such as conditions asso-
ciated with massive hyperoxaluria; (iii) certain crystal
species such as struvite, cystine, dihydroxyadenine (DHAd),
xanthine, or drugs are not found in normal urine and are
indicative of speciﬁc pathological conditions; and (iv) serial
determination of crystalluria is of help in the follow-up of
patients with severe forms of nephrolithiasis, as it reﬂects
the activity of stone disease and response to therapeutic
measures.
In patients who suffer from stone disease, crystalluria
studies may speciﬁcally contribute to the diagnosis by
comparison to extensive metabolic evaluation. For
example, DHAd is not commonly measured in urine of
affected patients, whereas crystalluria is found in almost all
patients and establish unambiguously the diagnosis. Incystinuric patients, the diagnosis may be established either
by the observation of cystine crystals or by measuring
cystine excretion in urine. However, for the therapeutic
management of the patients, cystine concentration or
excretion is not sufﬁcient to predict stone recurrence,
whereas the presence of cystine crystals in urine and the
global crystal volume (GCV) of cystine may be a good
marker for predicting the risk of stone recurrence [4e6]. In
calcium stone formers, neither the 24 h excretion of cal-
cium, oxalate, phosphate, and citrate nor their respective
concentrations are able to predict the presence of crystals
and then the risk of stone recurrence, which may be
deduced from crystalluria studies [7]. Thus, crystalluria
examination is clinically relevant for either the diagnosis of
crystalline pathologies or the management of patients.
2. Protocol for crystalluria evaluation
To be informative, crystalluria analysis should follow an
adequate methodology and be performed in patient's usual
conditions of life and nutrition.
Urine sample should be taken in the fasting state, on
ﬁrst-voided morning urine, or on the second micturition,
because urine produced during the night is the most
concentrated and therefore carries the highest probability
of crystal formation.
The recommended protocol is described elsewhere
[8e10]. In short, urine sample should be brought to the
laboratory within 2 h of voiding, kept at room temperature,
and processed without delay [11].
First, urine pH is measured with a pHmeter (preferably)
or with double-color scale strips with a precision of 0.1
unit, and speciﬁc gravity is measured using a densitometer
(preferably) or a multichannel strip with a correction for
urine pH [12]. Then, a sample of urine is homogenized by
Fig. 2. Hexagonal crystal of caoxite (calcium oxalate trihydrate).
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put in a Malassez cell, and is examined by polarized light
microscopy. Microscopic examination includes urine
cytology, and comprehensive crystalluria evaluation is
based on the identiﬁcation of all crystal species, numera-
tion and measure of the size of crystals and aggregates and,
if relevant, the assessment of crystal volume. Fourier
transform infrared spectroscopy is used whenever needed
to conﬁrm the nature of unusual crystals.
Statistical comparisons regarding biochemistry of urine
with or without crystals (ANOVA) and the distribution of
crystals as a function of urine pH classes (chi-square test)
were performed with the NCSS statistical package (J. Hintz,
Gainesville, FL). A P value less than 0.05 was considered as
statistically signiﬁcant.
3. Nature and morphology of urinary crystals and
correlations with etiology
Urinary crystals have a great variety of morphologies.
Several textbooks dealing with the urinary sediment or
crystal analysis may help to identify metabolic or drug
crystals [13e15]. From a clinical point of view, crystals are
reﬂecting supersaturation of urine regarding one or several
chemical species. In our experience, correlations between
crystalluria and etiology of nephrolithiasis have been
established from microscopic examination of approxi-
mately 25,000 ﬁrst morning urine samples from 3000 pa-
tients for whom urine biochemistry parameters were
determined in the same samples and full etiological eval-
uation was available. In addition to the chemical nature of
common forms of nephrolithiasis, identiﬁcation of the
crystalline forms of CaOx, CaP, or UA crystals provides
important information that may orient toward speciﬁc
pathophysiological conditions, some corresponding to se-
vere forms of nephrolithiasis.3.1. Common types of urinary crystals
3.1.1. Calcium oxalates
Crystalluria made of CaOx crystals is the commonest
form of crystalluria found in stone formers. The main
determinant of CaOx crystal formation is urine supersatu-
ration owing to excessive concentration of calcium and
oxalate ions, reﬂected by their molar product (pCaOx). AFig. 1. (a) Typical oval crystals of whewellite with a depressedvery low concentration of low molecular weight inhibitors
such as citrate and magnesium ions may also induce crys-
talluria [16,17]. However, CaOx crystals do not come under
a homogeneous category, as they present commonly in two
different forms, CaOx monohydrate (COM, or whewellite)
and CaOx dihydrate (COD, or weddellite) according to the
respective concentrations of Ca and Ox ions (Fig. 1). A third
form, namely CaOx trihydrate or caoxite may be scarcely
found in urine (Fig. 2).
Simultaneous determination of calcium and oxalate
concentrations and search for crystalluria in 21,220 urine
samples from calcium stone formers allowed to deﬁne
threshold values for the risk of CaOx crystal formation [18].
Thus, the concentration of oxalate ions associated with the
formation of CaOx crystals, determined as the inﬂexion of
the curve plotting the percentage of urine samples exhib-
iting the presence of CaOx crystals versus the concentration
of oxalate, was 0.3 mmol/l (Fig. 3).
The concentration of calcium ions associated with the
formation of CaOx crystals, determined as the inﬂexion of
the curve plotting the percentage of urine samples exhib-
iting the presence of CaOx crystals versus the concentration
of calcium, was 3.8 mmol/l (Fig. 4).core. (b) Bipyramidal (octahedral) crystals of weddellite.
Fig. 3. Inﬂuence of oxalate concentration on the occurrence of CaOx
crystalluria.
Fig. 5. Distribution of crystal phases of calcium oxalate according to the
calcium/oxalate molar ratio in urine samples. Data collected from 6869 urine
samples that contained calcium oxalate crystals. ***P < 0.00001 vs rCaOx > 14.
xxP < 0.001, xxxP < 0.00001 vs 5  rCaOx < 14.
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rolithiasis, predominance of COM (whewellite) crystals is
associated with an increased concentration of oxalate [18],
whereas predominance of COD (weddellite) crystals is
mostly associated with hypercalciuria [18,19]. COM crys-
talluria was found in 66% of urine samples with a high
oxalate concentration (>0.3 mmol/l) facing a relatively low
calcium concentration (Ca < 2 mmol/l), whereas COD
crystals were found in 99% of samples with both a high
calcium concentration (>3.8 mmol/l) and a normal or
relatively low oxalate concentration.
In fact, whewellite is preponderantly formed when the
molar ratio of Ca/Ox (rCaOx) is <5, that is, in urine with a
high Ox concentration facing a relatively low Ca concen-
tration. On the contrary, weddellite is almost exclusively
formed when rCaOx is >14, that is, in urine of high Ca con-
centration facing a normal or slightly augmented Ox con-
centration. In the interval estimate, both forms are formed
in variable proportions (Fig. 5).
3.1.1.2. Inﬂuence of pH on CaOx crystalluria. Although crys-
tallization of CaOx is poorly dependent on urine pH [20],
we observed in our whole series of urine samples from
stone formers that a urine pH beyond 6.5 is associated with
a lower frequency of COD crystalluria, the calcium-
dependent form of CaOx, probably because of a higherFig. 4. Inﬂuence of calcium concentration on the occurrence of CaOx
crystalluria.citrate activity [21]. Indeed, citric acid is a tricarboxylic acid
with three ionizable acid functions, of which the pKa are,
respectively, 3.13, 4.76, and 6.40. Consequently, the pH level
is able to inﬂuence ionization of citrate, making citrate3 in
neutral or alkaline urine more efﬁcient for complexing
calcium ions than do citrate2 in more acidic urine. More-
over, in alkaline urine, citrate is able to form larger amounts
of [CaCitPO4]4 ions which are soluble, thus reducing
signiﬁcantly urine supersaturation as suggested by Rodgers
et al. [22]. As a result, a signiﬁcant decrease in COD crys-
talluria is observed in the pH range >7.0 (Fig. 6). It was often
reported that calcium stone formers excrete less citrate
than healthy subjects, thus explaining, at least in part, the
formation of calculi. In our experience, COD crystalluria
peaked in the pH range 5e6.5. In this pH range, the mean
concentration of citrate in the presence of COD crystalluria
was 2.39 mmol/l, an obviously normal value [23e25] and
did not change signiﬁcantly for higher pH values. By
contrast, urine calcium concentration was lower in alkaline
urine (P < 0.00001) in comparison with more acidic sam-
ples, in association with a lower prevalence of COD crys-
talluria (Fig. 7). As shown in Fig. 8, this decrease was
associated with a signiﬁcant decrease in the calcium/Fig. 6. Inﬂuence of urine pH on the occurrence of CaOx crystalluria (whole
series of 21,220 urine samples). The percentage of urine samples containing
COD crystals was signiﬁcantly lower (P < 0.00001) in acidic urine (pH < 5)
and in alkaline urine (pH  7) as compared with urine in the intermediate
range of pH value, i.e., between 5.5 and 6.5.
Fig. 7. Mean concentrations of calcium, oxalate, and citrate in urine samples with (Crþ, n ¼ 3109) and without (Cr, n ¼ 18,111) COD crystals in relation to urine
pH. We observe that urine calcium concentration is 2e3 times higher in Crþ than in Cr urine samples. Values are expressed as the mean ± SEM.
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without crystals as well. These data suggest that calcium
excretion is reduced in alkaline urine. Of note, the higher
level of creatinine in patients with COD crystalluria (Crþ)
for all values of urine pH suggests that Crþ is, at least in
part, associatedwith a lower diuresis or with an insufﬁcient
water intake before the bedtime. Thus, a moderate alkali-
zation of urine could beneﬁt CaOx stone formers by
reducing the risk of COD crystallization, especially in pa-
tients with heavy hypercalciuria.
3.1.1.3. Crystal morphology. Morphology of weddellite crys-
tals depends on the level of calciuria. Usually, COD crystals
are octahedral presenting as two ﬂat pyramids joined at
their bases (Fig. 1). However, as calcium concentration in-
creases, the interface between pyramids enlarges, leading
to COD crystals with a dodecahedral aspect (Fig. 9). The
presence of dodecahedral COD crystals (i.e., bipyramidal
with a thick zone between the two pyramids) is indicativeFig. 8. Change in the calcium/creatinine (Ca/Creat) molar ratio in relation to
urine pH. Although the Ca/Creat ratio was nearly two times higher in urine
samples with (Crþ, n ¼ 3109) than without (Cr COD , n ¼ 18,111) COD
crystals and slightly increased with pH up to pH 7, this ratio markedly de-
creases beyond pH 7 in both cases. Values are expressed as the mean ± SEM.
**P < 0.01, ***P < 0.00001 vs pH < 6 or pH  7.of heavy hypercalciuria, usually over 7 mmol/l. As shown in
Fig. 10, the frequency of dodecahedral COD crystals in-
creases with increasing urine calcium concentration.
As shown in Fig. 1, COM crystals present as oval forms
with a depressed part in the center of the crystals. It is the
common form of COM in urine. However, in some cases,
COM crystals may present as narrow hexagons or lozenges,
which suggest an ethylene glycol poisoning [10].
3.1.1.4. Quantitative aspect. An abundant amount of pure
COM crystals (>200/mm3) is highly suggestive of primary
hyperoxaluria type 1 (PH1) and in our experience was
found in virtually all untreated patients with primary
hyperoxaluria, although the diseasemay be associatedwith
lower counts of COM crystals, especially when calcium
concentration is very low (<1 mmol/l).
3.1.2. Calcium phosphates
Most CaP crystals are made of calcium orthophosphates,
mainly amorphous carbonated CaP and/or carbapatite, and
present at light microscopy as small granulations giving no
polarization (Fig. 11). Carbapatite crystals were mostly
found in hypercalciuric urines with a normal pH (5.8e6.5),
whereas amorphous carbonated CaP was observed in
urines with a high pH (>6.6) and normal or near-normal
calcium and phosphate concentrations [26].
Brushite crystals, made of calcium and hydro-
genophosphate ions, present as sticks, which often form
large aggregates (Fig. 12). Brushite crystals were mainly
found in urines with both marked hypercalciuria ± hyper-
phosphaturia, and a pH of nearly 6.4. In addition, unlike
other CaP crystals, brushite is often associated with a
decreased citrate concentration and consequently a high
calcium/citrate molar ratio (average 8.28 vs 3.99 for other
CaP crystals, P < 0.0001). Also, the presence of brushite
crystals or aggregates >500/mm3, a very uncommon
ﬁnding, should prompt the search for primary hyperpara-
thyroidism [27].
Fig. 9. Two morphological aspects of dodecahedral crystals of weddellite: (a) polarizing microscopy; (b) light microscopy.
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urines whose pH is commonly >6.4 (Fig. 13).
3.1.3. Uric acid
UA crystals form in acidic urine. UA dihydrate is the
commonest form. It has the lowest crystallization pH (5.25)
and presents with various morphologies, typically as hex-
agonal or diamond-shaped crystals, characteristically hav-
ing a polychrome aspect in polarized light (Fig. 14).
Crystalluria made of UA dihydrate is suggestive of defective
renal ammoniagenesis as observed in the metabolic syn-
drome or type 2 diabetes [28]. Anhydrous UA and UA
monohydrate are less frequently observed and also form in
acidic urine, whereas amorphous UA (Fig. 15) precipitates
are found in urine with a high UA concentration in
moderately acidic pH.
Anhydrous UA presents as large polygonal crystals with
a monochrome aspect in polarized light.
As shown in Fig. 16, UA dihydrate forms mainly in very
acidic urine, whereas amorphous UA mainly depends on
the concentration of urate ions in urine.
3.1.4. Urate salts
The most frequent urate form is anhydrous ammonium
hydrogen urate. Its crystals form in alkaline urine or in theFig. 10. Occurrence (%) of dodecahedral crystals of weddellite as a function
of calcium concentration in urine.pH range of 6.3e7, depending on the associated metabolic
factors, and they exhibit various morphologies (Fig. 17).
Unlike ammonium urate crystals, crystals made of urate
salts such as sodium hydrogen urate, potassium quad-
riurate, calcium hydrogen urate, or magnesium hydrogen
urate are very uncommon. All of these species are observed
in neutral or alkaline urine.
3.1.5. Struvite
Crystals of magnesium ammonium phosphate (stru-
vite) form in strongly alkaline urine. Struvite crystals
typically have a “cofﬁn-lid” aspect (Fig. 18), but they also
present as other morphologies (Fig. 19). The presence of
struvite crystals, even in small amounts, in a markedly
alkaline urine (pH > 7) is indicative of urinary tract
infection (UTI) with urease-producing microorganisms,
usually Proteus mirabilis or certain strands of Escherichia
coli, Klebsiella pneumoniae, Staphylococcus aureus, Pseu-
domonas aeruginosa, or less frequently, Corynebacterium
urealyticum, responsible for encrusted cystitis and/or
pyelitis [29]. Finding of struvite crystals even in the
absence of overt UTI should prompt careful bacteriolog-
ical urine analysis to identify the responsible microor-
ganism, including culture on special media if a usualFig. 11. Agglomerate of small grains and irregular translucent plaque of
amorphous carbonated calcium phosphate.
Fig. 12. (a) Rod-shaped crystals of brushite. (b) Aggregate of brushite crystals.
Fig. 13. Inﬂuence of urine pH on calcium phosphate crystallization
(n ¼ 2800 urine samples).
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analysis.3.2. Infrequent types of urinary crystals
Other crystals are much less frequently found in urine.
They reﬂect the presence of rare hereditary stone diseases
or the renal elimination of drugs.
3.2.1. Hereditary stone diseases
Cystine crystals present as hexagonal slides often
forming macles of large dimensions (Fig. 20). They areFig. 14. Two morphological aspects of uric acid dihydrate crystals: (a) polychromatic
new crystals at the surface of the initial crystal; (b) polychromatic hexagonal crystpathognomonic of proximal tubular defects because of
mutations of the genes coding for membrane transporters
of dibasic amino acids [30].
2,8-Dihydroxyadenine crystals present as small round
crystals (about 5 mm in diameter) showing a characteristic
central black cross (“Maltese cross” aspect) at polarizing
microscopy (Fig. 21). They are found in patients with an
adenine phosphoribosyltransferase deﬁciency [31,32] and
may be responsible for progressive interstitial crystal
inﬁltration leading to end-stage renal failure [33e35].
Xanthine crystals present as refringent granulations or
sticks without a characteristic aspect, and Fourier trans-
form infrared analysis is required for accurate identiﬁca-
tion. Xanthine crystals are observed in two different
pathological conditions: (i) inherited xanthine dehydro-
genase deﬁciency, and (ii) long-term treatment with allo-
purinol in patients with hereditary hypoxanthine guanine
phosphoribosyltransferase deﬁciency.
Tyrosine, leucine, or potassium orotate crystals are very
infrequent. They reﬂect very rare metabolic diseases.
3.2.2. Drug-induced crystallurias
A few drugs, mainly antimicrobial or antiviral agents,
may crystallize in urine when used at high dose for several
days and, sometimes, for long periods [36]. They may be
responsible for stone formation or sometimes heavy
tubular precipitation and acute anuric renal failure
[37e43].diamond-shaped crystal seen at polarizing microscopy. Note the initiation of
als.
Fig. 15. Multiple polarized grains of amorphous uric acid.
Fig. 16. Respective inﬂuence of urine pH (left) and uric acid concentration (right)
precipitates.
Fig. 17. Various forms of ammoniu
M. Daudon et al. / C. R. Chimie 19 (2016) 1514e1526 1521In a patient presenting with acute oliguric renal failure
of no obvious cause, immediate search for crystalluria in
the few passed urine may allow proper diagnosis by iden-
tifying characteristic drug crystals. Rapid institution of
appropriate therapeutic measures such as modulation of
urinary pH and hydration often obtained recovery of renal
function even in patients with major renal impairment
[44].
Several sulfonamides may induce crystalluria (Fig. 22).
N-acetylsulfamethoxazole chlorhydrate, the main metab-
olite of sulfamethoxazole largely used for the treatment of
UTIs in combination with trimethoprim, forms crystals in
acidic urine. Its crystals with a losangic form (Fig. 22a)
resemble UA dihydrate, and those with a hexagonal or oval
form may be mistaken with cystine or whewellite crystals.on the formation of uric acid dihydrate crystals and amorphous uric acid
m hydrogen urate crystals.
Fig. 18. Typical cofﬁn-shaped crystal of struvite.
Fig. 20. Typical crystals of cystine.
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used in the treatment of cerebral toxoplasmosis, also
crystallizes in acidic urine (Fig. 22b), whereas crystals of N-
acetylsulfaguanidine, a metabolite of sulfaguanidine used
as intestinal antiseptic, are very infrequently observed.
Occasionally, other antibacterial agents such as ﬂuo-
roquinolones, aminopenicillines (particularly high-dose
amoxicillin), or ceftriaxone may induce heavy crystalluria
and intratubular precipitation with acute renal failure
(Fig. 23) [45,46].
Antiviral agents currently are a common cause of crys-
talluria, especially indinavir and now atazanavir. These
antiproteases, widely used in combination therapy in AIDS
patients, form very large bundles of drug needles
(150e250 mm or more) [37,47]. Of note, although indinavir
crystalluria is often abundant with large aggregates, ata-
zanavir crystals are commonly dispersed and poorly
aggregated (Fig. 24). Aciclovir, used for the treatment of
herpes virus infections, also forms crystals with an aspect
of long, thin needles that may form aggregates (Fig. 25)
[48].Fig. 19. Large crystal of struvite seen by polarizing microscopy.Felbamate, an anti-seizure drug, was also reported to
crystallize in urine [49].
4. Crystalluria and follow-up of stone formers
Both qualitative and quantitative aspects of crystalluria
studies may be clinically relevant for the follow-up of stone
formers.
4.1. CaOx crystalluria
4.1.1. Calcium concentration
The validity of a value of 3.8 mmol/l for urinary calcium
concentration as the threshold for the risk of calcium
stone formation was conﬁrmed in vivo in a prospective
caseecontrol study including 181 patients with severe,
recurrent idiopathic calcium nephrolithiasis who were
followed for at least 3 years (up to 20 years) with search
for crystalluria at each visit and all of whom receiving the
same therapeutic recommendations [7]: 72 patients
experienced a new stone episode within a mean time of
2.4 years, whereas the other 109 had no recurrence during
a follow-up of 6.9 years. In this study, ROC curve analysis
determined the cutoff value of urinary calcium concen-
tration indicative of the risk of stone recurrence at
3.78 mmol/l.
A similar threshold value was also evidenced by other
groups. In a prospective incidence study by Curhan et al.
[50] in the USA, the risk of formation of calcium stones
increased signiﬁcantly in patients of either gender when
urinary calcium concentrationwas in excess of 3.75mmol/l.
In a prospective Italian study, the corresponding risk value
was estimated at 3.63 mmol/l [51].
Thus, on the basis of such concordant data, a calcium
concentration <3.8 mmol/l should be adopted as the rec-
ommended goal to reduce the risk of calcium stone for-
mation or recurrence.
4.1.2. Correlation of crystalluria with activity of the lithogenic
process: crystalluria index
Crystalluria is more frequently found in stone formers
than among healthy people, although some crystals may
Fig. 21. Small spherical crystals of dihydroxyadenine: (a) light microscopy; (b) polarizing microscopy. Note the typical aspect under polarized light showing that
all crystals exhibit a Maltese cross.
Fig. 22. (a) Crystals of N-acetylsulfamethoxazole hydrochloride resembling uric acid dehydrate crystals (light microscopy). (b) Aggregated crystals of N-ace-
tylsulfadiazine (polarizing microscopy).
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especially during the hours after a meal.
As there is a necessary relationship between precipita-
tion of urinary crystals and formation of stones, we
reasoned that the risk of stone formation would increase
with an increased frequency of crystalluria. By evaluating
the presence or absence of crystals in ﬁrst morning urine
samples at each visit in 204 calcium stone formers pro-
spectively followed at our institution for a median duration
of 7 years (5e15 years), we observed sustained crystalluriaFig. 23. Isolated or aggregated large needle-shaped crystals of amoxycillin
trihydrate (polarizing microscopy).to be indicative of persistent stone disease activity and
highly predictive of the recurrence of stones. The presence
of crystals in 50% or more of urine samples was associated
with stone recurrence in 87% of cases, whereas stone
recurrence was observed in only 9% of patients with less
frequent crystalluria (Fig. 26). In another study, we found
that around 90% of recurrent stone formers exhibited
crystals in at least 50% of urine samples [52].
Accordingly, we proposed a “crystalluria index” deﬁned
as the ratio of the number of urine samples containing
crystals to the total number of examined samples in a given
patient, with a crystalluria index 0.50 as the threshold
value indicative of persistent lithogenic activity and risk of
stone recurrence [7]. In clinical practice, the interval of time
between two successive urine sample examinations should
be about 6 months (or less in the case of an active neph-
rolithiasis) for an optimized follow-up of the patients. Ac-
cording to the ROC curve analysis, the cutoff value of a
crystalluria index for the risk of developing stone recur-
rence was 0.50, and multivariate analysis by the Cox model
identiﬁed a crystalluria index of 0.50 as the most powerful
independent predicting parameter, with a hazard ratio of
16.8 [7].4.2. Quantitative aspects: GCV
Crystalluria abundance is usually evaluated by simply
counting the number of crystals per cubic millimeter. It
Fig. 24. Crystals of antiprotease drugs used to treat HIV patients. (a) and (b) Aggregates of indinavir monohydrate crystals. (c) and (d) Needle-shaped crystals of
atazanavir. The crystals are commonly associated with white cells (arrow).
Fig. 25. Needle-shaped crystals of aciclovir (polarizing microscopy).
Fig. 26. Relation between the occurrence of crystalluria in serial urine
samples and the risk of stone recurrence in stone formers.
NRSF ¼ nonrecurrent stone formers, RSF ¼ recurrent stone formers over a
period of 7 years of follow-up.
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volume per cubic millimeter. Such quantiﬁcation is espe-
cially useful for the management of severe forms of
nephrolithiasis.
Disappearance of crystalluria is the best indicator of
well-controlled lithogenic activity. This result is generally
reached in patients with common forms of calcium or UA
nephrolithiasis. However, total disappearance of crys-
talluria is a difﬁcult goal to achieve in genetic diseases, such
as primary hyperoxaluria and cystinuria, which have a very
active, permanent crystallization process. In these severe
diseases, a partial decrease in the amount of crystals pre-
sent in urine samples guided by the determination of GCV
is a more attainable goal often sufﬁcient to reduce stone
formation.
Determination of the global volume occupied in urine
by a given crystal species per volume unit provides the
most precise estimation of the abundance of crystalluria.
The GCV (expressed as mm3/mm3) is calculated as the
product of the number of crystals per cubic millimeter
multiplied by the average size of crystals in micrometers
and by a numeric factor taking into account the geometric
form of crystals speciﬁc for each species [10].
Formulae proposed for the calculation of GCV of crys-
tallurias of whewellite, weddellite, cystine, or dihydrox-
yadenine are presented in Figs. 27 and 28.
By comparing clinical outcomes and variations in crystal
volume in serial urine samples, we could determine the
thresholds of GCV associated with stone recurrence in PH1
and cystinuria, thus deﬁning the desirable goals to achieve.
In PH1 patients, a crystal volume <500 mm3/mm3 was
associated with a lowered risk of tubular plugging with
COM crystals in the days following combined liverekidney
transplantation, a crucial period when considerable
amounts of CaOx stored in bones are excreted through the
kidneys after restoration of renal function, with the risk of
massive tubular obstruction and loss of the kidney trans-
plant [53]. By closelymonitoring CaOx crystal volume, early
Fig. 27. Crystal shapes of whewellite and weddellite used for the calculation of global crystal volume (GCV) of calcium oxalate crystalluria. N ¼ number of
crystals/mm3; L ¼ average length (mm) of the whewellite crystals; D ¼ average diagonal or length (mm) of weddellite crystals.
M. Daudon et al. / C. R. Chimie 19 (2016) 1514e1526 1525post-transplant care of PH1 children could be optimized
[54,55] and long-term outcome was improved [56].
In cystinuric patients, measurement of cystine excretion
is not recommended for the management of patients to
prevent stone recurrence [57]. Crystalluria study may be
clinically relevant [6,58]. The presence of >25 cystine crys-
tals/mm3 is indicative of an active lithogenic process,
although a lesser number of cystine crystals may be asso-
ciated with stone formation, especially in the case of large
crystals. Therefore, determination of the GCV of cystine
appears as a better means to assess the risk of cystine stone
formation during the follow-up of patients. Thus, a cystine
crystal volume>3000 mm3/mm3was shown to be predictiveFig. 28. Formulae proposed for calculation of the global crystal volume (GCV) of cystof next recurrence of cystine stones, whereas a stable lower
value was associated with a lack of recurrence [6,59].
5. Conclusions
The search for crystalluria in stone former patients af-
fords useful information as to the likely mechanisms of
lithogenesis in common forms of calcium nephrolithiasis.
Preponderance of COM or COD crystalline phases of CaOx
orients toward a lithogenic condition predominantly asso-
ciated with hyperoxaluria or hypercalciuria, respectively.
The identiﬁcation of peculiar chemical species such as
struvite, cystine, dihydroxyadenine, or xanthine is ofine crystals and 2,8-dihydroxyadenine in urine. N ¼ number of crystals/mm3.
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of genetic diseases such as cystinuria and dihydrox-
yadeninuria, which require speciﬁc therapy. Determination
of the GCV allows to assess the efﬁcacy of therapeutic
measures in severe genetic diseases such as primary
hyperoxaluria and cystinuria. Crystalluria index was clearly
shown as the best marker for predicting stone recurrence.
In addition, other criteria such as the size of COD crystals or
the presence of heterogeneous nucleation process may be
relevant for identifying particular metabolic disorders in
urine or the risk of recurrence in some patients [60].
In all types of renal stone disease, especially in the most
severe forms, serial search for crystalluria appears as a
valuable tool for identifying patients with active crystal
formation and at risk of forming kidney stones, therefore
allowing to timely institute or modify therapeutic mea-
sures to prevent stone recurrence.
Of note, crystalluria was rarely studied in normal sub-
jects [1]. Thus, the interest of studying crystalluria to pre-
dict a ﬁrst stone formation in healthy subjects was never
assessed. However, it was recently found that high values of
risk indices such as the Tiselius index, reﬂecting high urine
concentration of lithogenic factors, were associated with a
high occurrence of CaOx crystalluria in healthy subjects,
suggesting that crystalluria study could be, in stone formers
and in healthy subjects as well, an interesting tool for
detecting a possible risk of stone formation [61]. These
preliminary results require further investigations to be
validated on a larger series of normal subjects.
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